Clearstead Advisors
TRDA icon

Clearstead Advisors’s Entrada Therapeutics TRDA Stock Holding History

Clearstead Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04K Buy
+141
New +$1.35K ﹤0.01% 2674
2025
Q4 		– Sell
-115
Closed -$667 – 3243
2025
Q3 		$667 Buy
115
+102
+785% +$597 ﹤0.01% 2692
2025
Q2 		$88 Buy
+13
New +$105 ﹤0.01% 2630

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Clearstead Advisors's TRDA Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Entrada Therapeutics (TRDA) in Q2 2026: 141 shares worth $1.04K. The stake represents ﹤0.01% of the portfolio and ranks #2674 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in TRDA as recently as Q3 2025.

Clearstead Advisors first reported a position in TRDA in Q2 2025 and has held it in 3 quarters since. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Clearstead Advisors held 141 shares of Entrada Therapeutics worth $1.04K as of Q2 2026.
  • Entrada Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Entrada Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2674 holding.
  • Clearstead Advisors first reported a position in Entrada Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.